We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
AGI | LSE:AGI | London | Ordinary Share | IE00B0YT0Q82 | ORD EUR0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAGI
RNS Number : 8084W
AGI Therapeutics plc
03 February 2012
AGI Therapeutics plc
("AGI" or the "Company")
Offer Update
03 February 2012
1. Compulsory Acquisition
As at 1.00 p.m. (Dublin time) on 03 February 2012, valid acceptances of the Offer have been received in respect of 54,048,613AGI Shares, representing approximately 80.18 per cent. of AGI's issued share capital. Accordingly, Aravis Therapeutics Limited ("Aravis") intends to exercise its rights under the provisions of Section 204 of the Irish Companies Act 1963 to acquire compulsorily all outstanding AGI Shares not acquired or agreed to be acquired pursuant to the Offer on the same terms as the Offer. A further announcement about this will be made in due course.
AGI Shareholders who have not yet accepted the Offer are urged to complete, sign and return their Forms of Acceptance in accordance with the procedure set out in the Offer Document as soon as possible. The Offer remains open for acceptance until 3.00 p.m. (Dublin time) on 17 February 2012.
2. Directorate Change
AGI announces that Ronan Lambe, Chris Blackwell, John O'Sullivan, Frank Kenny and Peter Sandys resigned their positions as Non-Executive Directors of the Company on 03 February 2012 following Aravis announcing that all of the conditions of its Offer have been waived and that accordingly its Offer is declared unconditional in all respects.
The AGI Board wishes to thank Ronan Lambe, Chris Blackwell, John O'Sullivan, Frank Kenny and Peter Sandys for their excellent contribution to the development of the Company and wishes them well for the future.
This announcement should be read in conjunction with the Offer Document dated 12 January 2012. Unless expressly defined in this announcement, defined terms used in this announcement shall have the same meanings as set out in the Offer Document.
Enquiries:
AGI Therapeutics plc Tel: +353 1 449 3254 David Kelly, CFO Davy Corporate Finance Tel: +353 1 679 6363 Financial adviser to AGI John Frain David Nangle Goodbody Corporate Finance Tel: +353 1 667 0420 Financial adviser to the Aravis Group Simon Howley Stephen Kane
Responsibility Statements
The directors of AGI accept responsibility for the information contained in this announcement relating to AGI. To the best of the knowledge and belief of the directors of AGI (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.
The directors of the Aravis Group accept responsibility for the information contained in this announcement relating to Aravis. To the best of the knowledge and belief of the directors of the Aravis Group (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.
Financial Advisers
Davy Corporate Finance which is regulated by the Central Bank of Ireland, is acting exclusively for AGI and no one else in connection with the Offer and will not be responsible to anyone other than AGI for providing the protections afforded to customers of Davy Corporate Finance or for providing advice in relation to the Offer or any other matters referred to in this announcement.
Goodbody Corporate Finance which is regulated by the Central Bank of Ireland, is acting exclusively for the Aravis Group and no one else in connection with the Offer and will not be responsible to anyone other than the Aravis Group for providing the protections afforded to customers of Goodbody Corporate Finance or for providing advice in relation to the Offer or any other matters referred to in this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CASBKNDBABKDFBK
1 Year AGI Chart |
1 Month AGI Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions